Mostly Markets
Subscribe
Stocks/Health Care/Biotechnology

Regeneron PharmaceuticalsREGN

Biotechnology · Tarrytown, New York · In the S&P 500
High qualityCheaper than peers
$927.89+13.33%After hours: $926.00 (−0.20%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 42.1% over 1 year
Regeneron Pharmaceuticals over 1 yearDaily close, $, to 30 Oct 2026
$600$700$800$900Nov2026MarMayJulSep$927.89$600$800NovMarJul$927.89
Source: Nasdaq daily closes
Market value$95.53B
Price to earnings22.7x
Forward P/E14.3x
Dividend yield0.41%
Year to date+20.2%
One year+42.1%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$600.66$927.89

Quality and valuation

How Regeneron Pharmaceuticals compares with other health care stocks. A description, not a recommendation.

Regeneron Pharmaceuticals and 7 biotechnology peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: stronger than mostValuation: cheaper than most

A stronger business than most health care companies, priced below most of them.

Regeneron Pharmaceuticals trades at 14.3 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +9.3% vs +8.1%
  • More profitable (operating margin): 24.7% vs 13.3%
  • Turns more of its sales into cash: 24.2% vs 15.9%
REGN trades at 14.3x forward earnings, below the sector medianForward p/e, Biotechnology peers
REGN14.3xGILD19.4xABBV19.6xAMGN19.8xBIIB20.5xVRTX29.3xINCY61.0xSector median 19.1xREGN14.3xGILD19.4xABBV19.6xAMGN19.8xBIIB20.5xVRTX29.3xINCY61.0xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 22.9x earnings, REGN is pricier than its average since Aug 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
20x30xAverage 18.3x2025202622.9x20x30xAverage 18.3x2025202622.9x
Source: Nasdaq prices; SEC filings

Financials

From Regeneron Pharmaceuticals's SEC filings, through the quarter ending 30 Jun 2026. Hover or tap a bar for its value.

Revenue grew 16.7% from a year earlierQuarterly revenue, $bn, latest Q2 ’26
$0bn$2bn$4bnQ3 ’24Q1 ’25Q3 ’25$4.3bnQ2 ’26$0bn$2bn$4bnQ3 ’24Q1 ’25Q3 ’25$4.3bnQ2 ’26
Source: SEC filings
Growth slowed to +16.7% last quarterRevenue growth, year on year, %
0%10%Q3 ’24Q1 ’25Q3 ’2516.7%Q2 ’260%10%Q3 ’24Q1 ’25Q3 ’2516.7%Q2 ’26
Source: SEC filings
Operating margin was 30.1% last quarterOperating income as a share of revenue, %
0%10%20%30%Q3 ’24Q1 ’25Q3 ’2530.1%Q2 ’260%20%Q3 ’24Q1 ’25Q3 ’2530.1%Q2 ’26
Source: SEC filings
Free cash flow was $3.8 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $bn
$0.0bn$0.5bn$1.0bnQ3 ’24Q1 ’25Q3 ’25$0.6bnQ2 ’26$0.0bn$0.5bn$1.0bnQ3 ’24Q1 ’25Q3 ’25$0.6bnQ2 ’26
Source: SEC filings
Last 12 monthsREGNSector median
Revenue growth+9.3%+8.1%
Operating margin24.7%13.3%
Free cash flow margin24.2%15.9%
Price to earnings22.7x30.2x

Stories on Regeneron Pharmaceuticals

We haven't written about Regeneron Pharmaceuticals yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Biotechnology, by market value.

CompanyPriceTodayYTDValue
ABBVAbbVie$294.89+1.41%+29.1%$521B
AMGNAmgen$466.01+1.15%+42.4%$252B
GILDGilead Sciences$170.68+3.06%+39.1%$212B
VRTXVertex Pharmaceuticals$558.88+3.50%+23.3%$142B
MRNAModerna$221.72−0.47%+651.8%$88.52B
BIIBBiogen$253.62+1.59%+44.1%$37.49B
INCYIncyte$120.39+3.07%+21.9%$24.40B